Heidelberg Pharma (HPHA) Resumen de Acciones
Heidelberg Pharma AG, empresa biofarmacéutica, centra su actividad en la oncología y los conjugados de amanitina dirigidos a anticuerpos (ATAC) en Alemania, Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
HPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Heidelberg Pharma AG
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €2.75 |
| Máximo en las últimas 52 semanas | €5.36 |
| Mínimo de 52 semanas | €2.33 |
| Beta | 0.74 |
| Cambio en 1 mes | -0.36% |
| Variación en 3 meses | -9.24% |
| Cambio de 1 año | -17.66% |
| Variación en 3 años | -30.73% |
| Variación en 5 años | -58.08% |
| Variación desde la OPV | -94.80% |
Noticias y actualizaciones recientes
HPHA: Phase II Expansion And China Milestone Will Support Future Upside
Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside
Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?Recent updates
HPHA: Phase II Expansion And China Milestone Will Support Future Upside
Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside
Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have maintained their price target for Heidelberg Pharma at €6.75, citing updated assumptions that combine a very large projected revenue growth rate with an unchanged profit margin and a lower future P/E multiple. What's in the News Heidelberg Pharma plans to present preclinical data for its Amanitin-based ADC candidate HDP-103 for metastatic castration-resistant prostate cancer at the AACR Annual Meeting 2026 in San Diego, with a poster session scheduled on 21 April from 2:00 pm to 5:00 pm PDT (company announcement).
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
Catalysts About Heidelberg Pharma Heidelberg Pharma is a biotechnology company focused on developing antibody drug conjugates based on its proprietary Amanitin payload technology. What are the underlying business or industry changes driving this perspective?HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have kept their €6.75 price target for Heidelberg Pharma broadly unchanged, citing only marginal shifts in inputs such as the discount rate, long term profit margin assumptions and future P/E, which together leave their overall valuation view effectively steady. What's in the News Huadong Medicine has reached a development milestone under its 2022 license agreement with Heidelberg Pharma, triggering a milestone payment to Heidelberg Pharma, with financial details not disclosed (company announcement).HPHA: Steady Assumptions And Undervalued Outlook Will Support Future Upside
Analysts are keeping their price target for Heidelberg Pharma steady at €6.75. They cite only marginal tweaks to their discount rate and long term assumptions for revenue growth, profit margin and future P/E, rather than any shift in their core view on the stock.HPHA: New Leadership And High Growth Assumptions Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer of Heidelberg Pharma AG, effective immediately (Key Developments).HPHA: Leadership Transition And Stable Outlook Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75. They point to only small shifts in inputs such as the discount rate and the assumed future P/E multiple as reasons for maintaining their existing view.HPHA: Positive Trial Data And New Leadership Will Support Future Upside
Analysts have revised their price target for Heidelberg Pharma from €10.56 to €6.75, citing updated assumptions for revenue growth, profit margins, discount rates, and future P/E that change their assessment of the company’s risk profile and earnings potential. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer and appointed Dr Dongzhou Jeffery Liu as the new CEO with immediate effect.
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings.Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Heidelberg Pharma AG's ( ETR:HPHA ) price-to-sales (or "P/S") ratio of 15x might make it look like a strong sell right...Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Celebrations may be in order for Heidelberg Pharma AG ( ETR:HPHA ) shareholders, with the analysts delivering a...Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Heidelberg Pharma AG ( ETR:HPHA ) shareholders will have a reason to smile today, with the analysts making substantial...Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
The analysts covering Heidelberg Pharma AG ( ETR:HPHA ) delivered a dose of negativity to shareholders today, by making...We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, Heidelberg Pharma...Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Heidelberg Pharma AG ( ETR:HPHA ) shareholders might be concerned after seeing the share price drop 14% in the last...We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rentabilidad de los accionistas
| HPHA | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -1.8% | -1.0% | 0.6% |
| 1Y | -17.7% | -11.9% | 0.2% |
Rentabilidad vs. Industria: Los resultados de HPHA fueron inferiores a los de la industria German Biotechs, que obtuvo un rendimiento del -11.9% el año pasado.
Rentabilidad vs. Mercado: HPHA obtuvo unos resultados inferiores a los del mercado German, que fueron del 0.2% el año pasado.
Volatilidad de los precios
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Precio estable de las acciones: HPHA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HPHA (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1997 | 111 | Jeffery Liu | heidelberg-pharma.com |
Heidelberg Pharma AG, empresa biofarmacéutica, centra su actividad en la oncología y los conjugados de amanitina dirigidos a anticuerpos (ATAC) en Alemania, Estados Unidos y a escala internacional. Entre sus principales productos candidatos figura el HDP-101, un anticuerpo anti-BCMA, en estudio de fase I/IIa para el tratamiento del mieloma múltiple en recaída o refractario. La empresa desarrolla el HDP-102, un anticuerpo y el compuesto Amanitin, que ha completado el desarrollo preclínico para el tratamiento del linfoma no Hodgkin; el HDP-103, un candidato propio ATAC para tratar el cáncer de próstata metastásico resistente a la castración; el HDP-104 para el tratamiento de tumores gastrointestinales; el HDP-201 para el tratamiento del cáncer colorrectal; y el TAK-ATAC para el tratamiento oncológico.
Resumen de fundamentos de Heidelberg Pharma AG
| Estadísticas fundamentales de HPHA | |
|---|---|
| Capitalización bursátil | €128.66m |
| Beneficios(TTM) | -€40.62m |
| Ingresos (TTM) | €2.65m |
¿Está HPHA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HPHA | |
|---|---|
| Ingresos | €2.65m |
| Coste de los ingresos | €602.44k |
| Beneficio bruto | €2.05m |
| Otros gastos | €42.67m |
| Beneficios | -€40.62m |
Últimos beneficios comunicados
Feb 28, 2026
Próxima fecha de beneficios
Jul 15, 2026
| Beneficios por acción (BPA) | -0.87 |
| Margen bruto | 77.28% |
| Margen de beneficio neto | -1,531.69% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado HPHA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 14:51 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/02/28 |
| Ingresos anuales | 2025/11/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Heidelberg Pharma AG está cubierta por 9 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Bruno Bulic | Baader Helvea Equity Research |
| Christian Weiz | Baader Helvea Equity Research |
| Robin Davison | Edison Investment Research |